Source Nutraceutical, Inc (SNI)
Enabling Quick And Compliant Market Entry

Companies across the pharmaceutical and health sectors need to get products on the shelf and into the hands of patients in a seamless and efficient manner. However, they often struggle to achieve this due to the complex regulatory processes and evidence required.

When developing and marketing a pharmaceutical, it is also challenging to identify the right study design and population for the therapeutic area in question. Failing to gain this evidence quickly and properly can make or break a product’s market launch.

As a full-service solution provider specializing in pharmaceutical R&D, clinical trials, and regulatory affairs, Source Nutraceutical, Inc. (SNI) acts as the strategic partner for market compliance, both in Canada and globally.

Whether companies aspire to launch a new product, design the right study to meet marketing objectives or validate a new claim, SNI can help at every step of the way. Rather than outsourcing to multiple agencies, the company’s teams work collaboratively to bring regulatory, clinical research, and packaging/labeling creative solutions together for quick, compliant market entry.

“We are problem-solvers. Everything we do, from the beginning, has been about identifying our customers’ problems and then working to develop a solution to overcome them,” says Bernie Desgagnes, the President and CEO at SNI.

Over 18 years of business, SNI has provided strategic consulting, regulatory compliance, clinical trials, and packaging design services to more than 600 companies from small independent brands to global organizations. The company boasts an in-house team of regulatory affairs and clinical research specialists, graphic designers, and bilingual translators—all working together to validate the efficacy and market potential of a range of pharmaceutical products in diverse therapeutic areas.

“Our competitors simply cannot match our scope of services and speed-to-market,” says Desgagnes.

SNI keeps its services in-house, with new (and expanding) pharmaceutical clinical infrastructure. Of note is the clinical team including medical doctors, Ph.D. researchers, and more with a collective 100+ years of experience. Given that recruitment is consistently a challenge, SNI has access to a wide base of study populations, including over a million underserved Western Canadians with a high incidence of metabolic and cardiovascular conditions. The company has a strong track record not just in pharma but also in dietary supplements, natural health products, food, cosmetics, and medical devices. To date, over 105 clinical trials have been completed by the team.

“From pre-market planning to commercialization, we determine our client’s objectives and develop strategic solutions to help meet (and exceed!) project requirements. Our multi-disciplinary team will help support your drug development from early-stage planning, design, and implementation right at our facility. Underpinning it all is deep regulatory knowledge of the biggest risks likely to affect your molecule or formulation reaching the market,” says Krista Coventry, Senior Director of Clinical Affairs and Regulatory Strategy.

For instance, SNI recently completed a clinical study to investigate/validate an innovative diabetes and prediabetes diagnostic screening tool for SciMar’s Wellness Transformation Network. Today, SNI is continuing to manage SciMar’s extensive diabetes clinical research program, including the development of its novel therapeutic treatment.

“Innovation is a key driver in advancing health and wellness research to improve lives across the globe,” informs Coventry. “As a CRO, helping companies understand what needs to be done, and planning a roadmap to get there with support from a specialized team, enables clients to bring innovative therapeutics to market.”